Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
AUS.: +61-2-4786-0457
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Metabolic Disorder Therapeutics Market 2020 By Manufacturers, Regions, Type, And Application, Forecast To 2026

  • Purchase Options

 

Summary

The global Metabolic Disorder Therapeutics Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019. 

The Metabolic Disorder Therapeutics Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Metabolic Disorder Therapeutics Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.

The Key Manufacturers covered in this Report:-

  • Novo Nordisk A/S
  • Sanofi S.A.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck KgaA
  • Amgen, Inc.
  • AstraZeneca PLC
  • Actelion Pharmaceuticals Ltd.
  • Shire PLC
  • AbbVie, Inc.
  • Biocon Ltd.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Cipla, Inc.
  • CymaBay Therapeutics, Inc.

By the Product Type, the market is primarily segmented into:

  • Lysosomal Storage Diseases
  • Diabetes
  • Obesity
  • Inherited Metabolic Disorders
  • Hypercholesterolemia
  • Market segment by Application, split into
  • Oral
  • Parenteral
  • Others

By Applications, the market is segmented into:

  • Oral
  • Parenteral
  • Others

The Report covers the following Regions:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines
    • Vietnam
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Central & South America
    • Brazil
  • Middle East & Africa
    • Turkey
    • GCC Countries
    • Egypt
    • South Africa

Objective of the Metabolic Disorder Therapeutics Market Report:

  • To assess the size of the market by value and volume
  • Analyze the Metabolic Disorder Therapeutics Market in terms of regions and major countries
  • Highlight recent developments and trends in the market
  • Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
  • Determine share of the Metabolic Disorder Therapeutics Market in terms of various segments such as by product type, application, and end-user
  • Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
  • Discuss major factors that impact growth of the Metabolic Disorder Therapeutics Market

The Metabolic Disorder Therapeutics Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Metabolic Disorder Therapeutics Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders:

  • Material suppliers/wholesalers
  • Market Distributors/traders
  • Regulatory bodies
  • Research organizations, and consulting firms
  • Commercial research & developments (R&D)
  • Trade associations and industry bodies
  • Importers and exporters
  • End-use industries

Available Customizations:

Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lysosomal Storage Diseases
1.4.3 Diabetes
1.4.4 Obesity
1.4.5 Inherited Metabolic Disorders
1.4.6 Hypercholesterolemia
1.5 Market by Application
1.5.1 Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Oral
1.5.3 Parenteral
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends by Regions
2.1 Metabolic Disorder Therapeutics Market Perspective (2015-2026)
2.2 Metabolic Disorder Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorder Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Metabolic Disorder Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porters Five Forces Analysis
2.3.5 Metabolic Disorder Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Metabolic Disorder Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorder Therapeutics Players by Market Size
3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Metabolic Disorder Therapeutics Market Concentration Ratio
3.2.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2019
3.3 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.4 Key Players Metabolic Disorder Therapeutics Product Solution and Service
3.5 Date of Enter into Metabolic Disorder Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2021-2026)

5 Metabolic Disorder Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Metabolic Disorder Therapeutics Market Size by Application (2015-2020)
5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size (2015-2020)
6.2 Metabolic Disorder Therapeutics Key Players in North America (2019-2020)
6.3 North America Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
6.4 North America Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size (2015-2020)
7.2 Metabolic Disorder Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
7.4 Europe Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Metabolic Disorder Therapeutics Market Size (2015-2020)
8.2 Metabolic Disorder Therapeutics Key Players in China (2019-2020)
8.3 China Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
8.4 China Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Metabolic Disorder Therapeutics Market Size (2015-2020)
9.2 Metabolic Disorder Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
9.4 Japan Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Metabolic Disorder Therapeutics Market Size (2015-2020)
10.2 Metabolic Disorder Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Metabolic Disorder Therapeutics Market Size (2015-2020)
11.2 Metabolic Disorder Therapeutics Key Players in India (2019-2020)
11.3 India Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
11.4 India Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Metabolic Disorder Therapeutics Market Size (2015-2020)
12.2 Metabolic Disorder Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

13Key Players Profiles
13.1 Novo Nordisk A/S
13.1.1 Novo Nordisk A/S Company Details
13.1.2 Novo Nordisk A/S Business Overview and Its Total Revenue
13.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
13.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2015-2020))
13.1.5 Novo Nordisk A/S Recent Development
13.2 Sanofi S.A.
13.2.1 Sanofi S.A. Company Details
13.2.2 Sanofi S.A. Business Overview and Its Total Revenue
13.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
13.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.2.5 Sanofi S.A. Recent Development
13.3 Boehringer Ingelheim GmbH
13.3.1 Boehringer Ingelheim GmbH Company Details
13.3.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
13.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
13.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.3.5 Boehringer Ingelheim GmbH Recent Development
13.4 Eli Lilly and Company
13.4.1 Eli Lilly and Company Company Details
13.4.2 Eli Lilly and Company Business Overview and Its Total Revenue
13.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
13.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.4.5 Eli Lilly and Company Recent Development
13.5 Merck KgaA
13.5.1 Merck KgaA Company Details
13.5.2 Merck KgaA Business Overview and Its Total Revenue
13.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
13.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.5.5 Merck KgaA Recent Development
13.6 Amgen, Inc.
13.6.1 Amgen, Inc. Company Details
13.6.2 Amgen, Inc. Business Overview and Its Total Revenue
13.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
13.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.6.5 Amgen, Inc. Recent Development
13.7 AstraZeneca PLC
13.7.1 AstraZeneca PLC Company Details
13.7.2 AstraZeneca PLC Business Overview and Its Total Revenue
13.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
13.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.7.5 AstraZeneca PLC Recent Development
13.8 Actelion Pharmaceuticals Ltd.
13.8.1 Actelion Pharmaceuticals Ltd. Company Details
13.8.2 Actelion Pharmaceuticals Ltd. Business Overview and Its Total Revenue
13.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
13.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.8.5 Actelion Pharmaceuticals Ltd. Recent Development
13.9 Shire PLC
13.9.1 Shire PLC Company Details
13.9.2 Shire PLC Business Overview and Its Total Revenue
13.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
13.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.9.5 Shire PLC Recent Development
13.10 AbbVie, Inc.
13.10.1 AbbVie, Inc. Company Details
13.10.2 AbbVie, Inc. Business Overview and Its Total Revenue
13.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
13.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.10.5 AbbVie, Inc. Recent Development
13.11 Biocon Ltd.
10.11.1 Biocon Ltd. Company Details
10.11.2 Biocon Ltd. Business Overview and Its Total Revenue
10.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
10.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.11.5 Biocon Ltd. Recent Development
13.12 BioMarin Pharmaceutical, Inc.
10.12.1 BioMarin Pharmaceutical, Inc. Company Details
10.12.2 BioMarin Pharmaceutical, Inc. Business Overview and Its Total Revenue
10.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
10.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.12.5 BioMarin Pharmaceutical, Inc. Recent Development
13.13 Bristol-Myers Squibb Company
10.13.1 Bristol-Myers Squibb Company Company Details
10.13.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
10.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
10.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.13.5 Bristol-Myers Squibb Company Recent Development
13.14 Cipla, Inc.
10.14.1 Cipla, Inc. Company Details
10.14.2 Cipla, Inc. Business Overview and Its Total Revenue
10.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
10.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.14.5 Cipla, Inc. Recent Development
13.15 CymaBay Therapeutics, Inc.
10.15.1 CymaBay Therapeutics, Inc. Company Details
10.15.2 CymaBay Therapeutics, Inc. Business Overview and Its Total Revenue
10.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
10.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.15.5 CymaBay Therapeutics, Inc. Recent Development

14Analyst's Viewpoints/Conclusions

15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Table
List of Tables

Table 1. Metabolic Disorder Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
Table 3. Ranking of Global Top Metabolic Disorder Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Lysosomal Storage Diseases
Table 6. Key Players of Diabetes
Table 7. Key Players of Obesity
Table 8. Key Players of Inherited Metabolic Disorders
Table 9. Key Players of Hypercholesterolemia
Table 10. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Metabolic Disorder Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Metabolic Disorder Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Metabolic Disorder Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Metabolic Disorder Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Metabolic Disorder Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Metabolic Disorder Therapeutics Players
Table 21. Global Metabolic Disorder Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Metabolic Disorder Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019)
Table 24. Global Metabolic Disorder Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Metabolic Disorder Therapeutics Product Solution and Service
Table 27. Date of Enter into Metabolic Disorder Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Metabolic Disorder Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Metabolic Disorder Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Metabolic Disorder Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 37. North America Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 39. North America Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 43. Europe Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 49. China Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 51. China Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 55. Japan Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 67. India Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 69. India Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 73. Central & South America Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 77. Novo Nordisk A/S Company Details
Table 78. Novo Nordisk A/S Business Overview
Table 79. Novo Nordisk A/S Product
Table 80. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 81. Novo Nordisk A/S Recent Development
Table 82. Sanofi S.A. Company Details
Table 83. Sanofi S.A. Business Overview
Table 84. Sanofi S.A. Product
Table 85. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 86. Sanofi S.A. Recent Development
Table 87. Boehringer Ingelheim GmbH Company Details
Table 88. Boehringer Ingelheim GmbH Business Overview
Table 89. Boehringer Ingelheim GmbH Product
Table 90. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 91. Boehringer Ingelheim GmbH Recent Development
Table 92. Eli Lilly and Company Company Details
Table 93. Eli Lilly and Company Business Overview
Table 94. Eli Lilly and Company Product
Table 95. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 96. Eli Lilly and Company Recent Development
Table 97. Merck KgaA Company Details
Table 98. Merck KgaA Business Overview
Table 99. Merck KgaA Product
Table 100. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 101. Merck KgaA Recent Development
Table 102. Amgen, Inc. Company Details
Table 103. Amgen, Inc. Business Overview
Table 104. Amgen, Inc. Product
Table 105. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 106. Amgen, Inc. Recent Development
Table 107. AstraZeneca PLC Company Details
Table 108. AstraZeneca PLC Business Overview
Table 109. AstraZeneca PLC Product
Table 110. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 111. AstraZeneca PLC Recent Development
Table 112. Actelion Pharmaceuticals Ltd. Business Overview
Table 113. Actelion Pharmaceuticals Ltd. Product
Table 114. Actelion Pharmaceuticals Ltd. Company Details
Table 115. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 116. Actelion Pharmaceuticals Ltd. Recent Development
Table 117. Shire PLC Company Details
Table 118. Shire PLC Business Overview
Table 119. Shire PLC Product
Table 120. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 121. Shire PLC Recent Development
Table 122. AbbVie, Inc. Company Details
Table 123. AbbVie, Inc. Business Overview
Table 124. AbbVie, Inc. Product
Table 125. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 126. AbbVie, Inc. Recent Development
Table 127. Biocon Ltd. Company Details
Table 128. Biocon Ltd. Business Overview
Table 129. Biocon Ltd. Product
Table 130. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 131. Biocon Ltd. Recent Development
Table 132. BioMarin Pharmaceutical, Inc. Company Details
Table 133. BioMarin Pharmaceutical, Inc. Business Overview
Table 134. BioMarin Pharmaceutical, Inc. Product
Table 135. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 136. BioMarin Pharmaceutical, Inc. Recent Development
Table 137. Bristol-Myers Squibb Company Company Details
Table 138. Bristol-Myers Squibb Company Business Overview
Table 139. Bristol-Myers Squibb Company Product
Table 140. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 141. Bristol-Myers Squibb Company Recent Development
Table 142. Cipla, Inc. Company Details
Table 143. Cipla, Inc. Business Overview
Table 144. Cipla, Inc. Product
Table 145. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 146. Cipla, Inc. Recent Development
Table 147. CymaBay Therapeutics, Inc. Company Details
Table 148. CymaBay Therapeutics, Inc. Business Overview
Table 149. CymaBay Therapeutics, Inc. Product
Table 150. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 151. CymaBay Therapeutics, Inc. Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disorder Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Lysosomal Storage Diseases Features
Figure 3. Diabetes Features
Figure 4. Obesity Features
Figure 5. Inherited Metabolic Disorders Features
Figure 6. Hypercholesterolemia Features
Figure 7. Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Oral Case Studies
Figure 9. Parenteral Case Studies
Figure 10. Others Case Studies
Figure 11. Metabolic Disorder Therapeutics Report Years Considered
Figure 12. Global Metabolic Disorder Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Metabolic Disorder Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Metabolic Disorder Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Metabolic Disorder Therapeutics Market Share by Players in 2019
Figure 17. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2019
Figure 19. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Novo Nordisk A/S Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 28. Sanofi S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 30. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 32. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 34. Merck KgaA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 36. Amgen, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 38. AstraZeneca PLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 40. Actelion Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 42. Shire PLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 44. AbbVie, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 46. Biocon Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 48. BioMarin Pharmaceutical, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 50. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 52. Cipla, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 54. CymaBay Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us